Tian Jin-Hai, Liu Shi-Hai, Yu Chuan-Yang, Wu Li-Gang, Wang Li-Bin
The Biochip Research Center, General Hospital of Ningxia Medical University, Yinchuan, China, Yinchuan, China.
The Clinical Medicine College of Ningxia Medical University, Yinchuan, China.
Front Oncol. 2021 Sep 13;11:702082. doi: 10.3389/fonc.2021.702082. eCollection 2021.
Breast cancer (BC) is one of the commonly occurring malignancies in females worldwide. Despite significant advances in therapeutics, the mortality and morbidity of BC still lead to low survival and poor prognosis due to the drug resistance. There are certain chemotherapeutic, endocrine, and target medicines often used for BC patients, including anthracyclines, taxanes, docetaxel, cisplatin, and fluorouracil. The drug resistance mechanisms of these medicines are complicated and have not been fully elucidated. It was reported that non-coding RNAs (ncRNAs), such as micro RNAs (miRNA), long-chain non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) performed key roles in regulating tumor development and mediating therapy resistance. However, the mechanism of these ncRNAs in BC chemotherapeutic, endocrine, and targeted drug resistance was different. This review aims to reveal the mechanism and potential functions of ncRNAs in BC drug resistance and to highlight the ncRNAs as a novel target for achieving improved treatment outcomes for BC patients.
乳腺癌（BC）是全球女性中常见的恶性肿瘤之一。尽管治疗方面取得了显著进展，但由于耐药性，BC的死亡率和发病率仍然导致生存率低和预后不良。有某些化疗、内分泌和靶向药物常用于BC患者，包括蒽环类药物、紫杉烷类、多西他赛、顺铂和氟尿嘧啶。这些药物的耐药机制复杂，尚未完全阐明。据报道，非编码RNA（ncRNAs），如微小RNA（miRNA）、长链非编码RNA（lncRNAs）和环状RNA（circRNAs）在调节肿瘤发展和介导治疗耐药性方面发挥关键作用。然而，这些ncRNAs在BC化疗、内分泌和靶向耐药中的机制有所不同。本综述旨在揭示ncRNAs在BC耐药中的机制和潜在功能，并强调ncRNAs作为实现改善BC患者治疗结果的新靶点。
